After a decade of neglect
Many blockbuster drugs will lose their patent exclusivity
Should be stashing cash and making acquisitions
what about the new cancer drug they have in the FDA investigation process ? might Pfizer be worth a long-term ( 2-3 years) strategic...
Pfizer’s revenues in 3Q13 were better than expectations. The company’s stock price rose 1.7% after the earnings release as the company...
really, I would say it is not really expnesive. It will be expensive when fails to generate revenues and profits.
Pfizer has performed better than Merck and the reason for decline earnings + sales is patent expiry.